Economic issues in lung cancer

Seminars in Respiratory and Critical Care Medicine

Volumn 21, Issue 5, 2000, Pages 375-384

  Bordeleau, L ^a   Goodwin, P J ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Costs; Decision making; Lung cancer

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; NAVELBINE; PACLITAXEL; VINCRISTINE; VINDESINE;

CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MEDIASTINOSCOPY; OUTCOMES RESEARCH; PRIORITY JOURNAL; REVIEW;

EID: 0033819657     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-9400     Document Type: Review

References (41)

1. Cancer statistics 1996
2. Cost analysis of hospital treatment - Two chemotherapeutic regimens for non-surgical non-small cell lung cancer
3. The cost-effectiveness of four cisplatin-containing chemotherapy regimens in the treatment of stages III B and IV non-small cell lung cancer: An Italian perspective
4. Cost-effectiveness of collecting routine cytologic specimens during fiberoptic bronchoscopy for endoscopically visible lung tumor
5. Cost effectiveness of chest CT in T1N0M0 lung cancer
6. Cost-effectiveness of CT scanning compared with mediastinoscopy in the preoperative staging of lung cancer
7. Investigation for mediastinal disease in patients with apparently operable lung cancer
8. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small cell lung carcinoma
9. Cost-effectiveness of head CT in patients with lung cancer without clinical evidence of metastases
10. Application of an algorithm for staging small-cell lung cancer can save one-third of the initial evaluation costs
11. The cost of treating small cell lung cancer
12. Estimating the cost of lung cancer diagnosis and treatment in Canada: The POHEM model
13. Cost-effectiveness of cancer chemotherapy: An economic evaluation of a randomized trial in small-cell lung cancer
14. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer
15. The impact of therapy with figrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy
16. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy
17. Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor
18. Counting the costs of cancer chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer
19. Cost utility of chemotherapy and best supportive care in non-small cell lung cancer
20. Diagnostic and therapeutic approaches to lung cancer in Canada and their costs
21. Estimating the cost of lung cancer diagnosis and treatment in Canada: The POHEM model
22. Cost-effectiveness of vinorelbine alone or vinorelbine plun cisplatin for stage IV NSCLC
23. The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer
24. A comparison of the costs of paclitaxel and best supportive care in stage IV non-small-cell lung cancer
25. Overview of economic analysis of Le Chevalier vinorelbine study
26. Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer
27. Cost-effectiveness of paclitaxel plus cisplatin in advanced non-small-cell lung cancer
28. How attractive does a new technology have to be to warrant adoption with utilization? Tentative guidelines for using clinical and economic evaluations
29. Tentative guidelines for using clinical and economic evaluations revisited
30. A decision-making framework for chemotherapeutic interventions for advanced non-small cell lung cancer
31. An estimate of the cost-effectiveness of gemcitabine in stage IV non-small cell lung cancer
32. Economic value of gemcitabine compared to cisplatin and etoposide in non-small cell lung cancer
33. Phase II trial and cost analysis of fazarabine in advanced non-small cell carcinoma of the lung: A Southwest Oncology Group Study
34. Cost of combined modality interventions for stage III non-small-cell lung cancer
35. The economics of lung cancer management in Canada
36. Economic considerations in the care of lung cancer patients
37. Overview of outcomes research and management and its role in oncology practice
38. A piece of mind. Which hat do I wear?
39. Efficacy and cost-effectiveness of cancer treatment: Rational allocation of resources based on decision analysis
40. Does knowledge guide practice? Another look at the management of non-small-cell lung cancer